Effects of Therapeutic Agents on Estrogens in the Breast
OBJECTIVES:
- Learn the effects of selected chemotherapy agents on the profile of estrogen
metabolites, glutathione conjugates, and depurinating DNA adducts in urine from women
with breast cancer.
- Determine whether tamoxifen citrate or aromatase inhibitor alters the metabolism of
estrogens.
OUTLINE: Patients are stratified according to planned therapy (tamoxifen citrate vs
aromatase inhibitor).
Patients receive tamoxifen citrate or an aromatase inhibitor as planned. Urine samples (and
nipple aspirate fluid, if possible) are collected before beginning treatment and after 2-6
months of treatment. Samples are analyzed for 40 estrogen metabolites, conjugates, and
depurinating DNA adducts by ultraperformance liquid chromatography with tandem mass
spectrometric detection.
Patients' information, including race, body mass index, age at menarche, menopausal status,
age at menopause if applicable, smoking history, alcohol consumption, pregnancy history
including age at each pregnancy, lactation, history of benign breast disease, hysterectomy,
and disease type, is collected through medical record review.
Observational
Observational Model: Cohort, Time Perspective: Prospective
Comparison of the estrogen compounds in urine
before and after treatment with tamoxifen or an aromatase inhibitor for two-to-six months
No
Ercole Cavalieri, DSc
Principal Investigator
University of Nebraska
United States: Federal Government
081-05
NCT00569543
May 2005
August 2012
Name | Location |
---|---|
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
UNMC Eppley Cancer Center at the University of Nebraska Medical Center | Omaha, Nebraska 68198-7680 |